Compare Oscar Health Inc (OSCR) vs Tilray Brands Inc (TLRY) Price & Performance

Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.

The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.

TLRY trades at $4.23, down 1.63% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $2.19 billion in 2025 despite revenue growth to $821.31 million, reflecting deep profitability challenges. Analysts show cautious sentiment with 65% hold ratings, while recent news highlights expansion in medical cannabis and beverage segments amid ongoing regulatory uncertainty.

The outlook remains challenged by persistent losses and high debt-to-asset ratio of 12.25, though low P/S and P/B ratios suggest undervaluation. Key risks include profitability execution and federal cannabis policy shifts, while potential catalysts lie in international expansion and cost management improvements.